Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of fosgonimeton
NCT05511558Phase 1Completed
- Sponsor
- LeonaBio
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fosgonimeton in Alzheimer's disease (AD), sponsored by LeonaBio. Primary endpoints: Mass balance of total radioactivity from [14C]-Fosgonimeton (pre-dose), Mass balance of total radioactivity from [14C]-Fosgonimeton (up to 9 days) and 6 more. Started Jul 2022; status: completed.
02
Drugs
fosgonimeton
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05511558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511558.